1. Home
  2. ERII vs DRUG Comparison

ERII vs DRUG Comparison

Compare ERII & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Energy Recovery Inc.

ERII

Energy Recovery Inc.

HOLD

Current Price

$8.76

Market Cap

595.9M

Sector

Technology

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$63.69

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ERII
DRUG
Founded
1992
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
595.9M
707.1M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
ERII
DRUG
Price
$8.76
$63.69
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$17.07
$129.25
AVG Volume (30 Days)
1.0M
431.0K
Earning Date
05-06-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
5.00
N/A
EPS
N/A
N/A
Revenue
$134,987,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$20.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.83
$23.98
52 Week High
$18.31
$123.75

Technical Indicators

Market Signals
Indicator
ERII
DRUG
Relative Strength Index (RSI) 49.20 38.82
Support Level $8.14 $49.47
Resistance Level $11.58 $70.23
Average True Range (ATR) 0.47 4.63
MACD 0.11 0.55
Stochastic Oscillator 43.58 50.35

Price Performance

Historical Comparison
ERII
DRUG

About ERII Energy Recovery Inc.

Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: